Supernus Gets Partial Win In Drug Patent Row With Actavis
By Kurt Orzeck ( February 5, 2016, 10:58 PM EST) -- Supernus Pharmaceuticals Inc. won a partial victory Friday in its bid to stop Actavis Inc. from bringing a generic version of the epilepsy drug Oxtellar XR to market when a New Jersey federal judge ruled the planned generic would infringe two Supernus patents....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.